instruction
stringlengths 99
248
| response
stringlengths 178
304
| text
stringlengths 310
585
|
|---|---|---|
In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the No Triple - Class Refractory * group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Triple - Class Refractory * is No was 0.65 with a 95% confidence interval (CI) of (0.39, 1.09) | ### Instruction: In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the No Triple - Class Refractory * group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Triple - Class Refractory * is No was 0.65 with a 95% confidence interval (CI) of (0.39, 1.09) |
What is the PFS hazard ratio and 95% CI for No Triple - Class Refractory * patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Triple - Class Refractory * is No was 0.65 with a 95% confidence interval (CI) of (0.39, 1.09) | ### Instruction: What is the PFS hazard ratio and 95% CI for No Triple - Class Refractory * patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Triple - Class Refractory * is No was 0.65 with a 95% confidence interval (CI) of (0.39, 1.09) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Penta - Refractory is Yes patients | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Penta - Refractory is Yes patients
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with Yes Penta - Refractory | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with Yes Penta - Refractory
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for Yes Penta - Refractory patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for Yes Penta - Refractory patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Yes Penta - Refractory patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Yes Penta - Refractory patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at Yes Penta - Refractory? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at Yes Penta - Refractory?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for Yes Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel)? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for Yes Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Yes Penta - Refractory patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Yes Penta - Refractory patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Yes Penta - Refractory patients. Can you help? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Yes Penta - Refractory patients. Can you help?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the Yes Penta - Refractory group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the Yes Penta - Refractory group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the Yes Penta - Refractory group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the Yes Penta - Refractory group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
What is the PFS hazard ratio and 95% CI for Yes Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) | ### Instruction: What is the PFS hazard ratio and 95% CI for Yes Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is Yes was 0.63 with a 95% confidence interval (CI) of (0.17, 2.33) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Penta - Refractory is No patients | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Penta - Refractory is No patients
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with No Penta - Refractory | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with No Penta - Refractory
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for No Penta - Refractory patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for No Penta - Refractory patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for No Penta - Refractory patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for No Penta - Refractory patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at No Penta - Refractory? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at No Penta - Refractory?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for No Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel)? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for No Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for No Penta - Refractory patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for No Penta - Refractory patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for No Penta - Refractory patients. Can you help? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for No Penta - Refractory patients. Can you help?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the No Penta - Refractory group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the No Penta - Refractory group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the No Penta - Refractory group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the No Penta - Refractory group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
What is the PFS hazard ratio and 95% CI for No Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) | ### Instruction: What is the PFS hazard ratio and 95% CI for No Penta - Refractory patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Penta - Refractory is No was 0.49 with a 95% confidence interval (CI) of (0.37, 0.64) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Revised ISS Stage At Baseline is I or II patients | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Revised ISS Stage At Baseline is I or II patients
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with I or II Revised ISS Stage At Baseline | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with I or II Revised ISS Stage At Baseline
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for I or II Revised ISS Stage At Baseline patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for I or II Revised ISS Stage At Baseline patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for I or II Revised ISS Stage At Baseline patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for I or II Revised ISS Stage At Baseline patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at I or II Revised ISS Stage At Baseline? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at I or II Revised ISS Stage At Baseline?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for I or II Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel)? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for I or II Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for I or II Revised ISS Stage At Baseline patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for I or II Revised ISS Stage At Baseline patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for I or II Revised ISS Stage At Baseline patients. Can you help? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for I or II Revised ISS Stage At Baseline patients. Can you help?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the I or II Revised ISS Stage At Baseline group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the I or II Revised ISS Stage At Baseline group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the I or II Revised ISS Stage At Baseline group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the I or II Revised ISS Stage At Baseline group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
What is the PFS hazard ratio and 95% CI for I or II Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) | ### Instruction: What is the PFS hazard ratio and 95% CI for I or II Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is I or II was 0.48 with a 95% confidence interval (CI) of (0.36, 0.64) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Revised ISS Stage At Baseline is III patients | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Revised ISS Stage At Baseline is III patients
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with III Revised ISS Stage At Baseline | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with III Revised ISS Stage At Baseline
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for III Revised ISS Stage At Baseline patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for III Revised ISS Stage At Baseline patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for III Revised ISS Stage At Baseline patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for III Revised ISS Stage At Baseline patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at III Revised ISS Stage At Baseline? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at III Revised ISS Stage At Baseline?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for III Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel)? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for III Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for III Revised ISS Stage At Baseline patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for III Revised ISS Stage At Baseline patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for III Revised ISS Stage At Baseline patients. Can you help? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for III Revised ISS Stage At Baseline patients. Can you help?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the III Revised ISS Stage At Baseline group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the III Revised ISS Stage At Baseline group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the III Revised ISS Stage At Baseline group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the III Revised ISS Stage At Baseline group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
What is the PFS hazard ratio and 95% CI for III Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) | ### Instruction: What is the PFS hazard ratio and 95% CI for III Revised ISS Stage At Baseline patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Revised ISS Stage At Baseline is III was 0.86 with a 95% confidence interval (CI) of (0.39, 1.92) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Tumor Burden is < 50 % patients | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Tumor Burden is < 50 % patients
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with < 50 % Tumor Burden | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with < 50 % Tumor Burden
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for < 50 % Tumor Burden patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for < 50 % Tumor Burden patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for < 50 % Tumor Burden patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for < 50 % Tumor Burden patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at < 50 % Tumor Burden? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at < 50 % Tumor Burden?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for < 50 % Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel)? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for < 50 % Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for < 50 % Tumor Burden patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for < 50 % Tumor Burden patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for < 50 % Tumor Burden patients. Can you help? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for < 50 % Tumor Burden patients. Can you help?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the < 50 % Tumor Burden group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the < 50 % Tumor Burden group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the < 50 % Tumor Burden group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the < 50 % Tumor Burden group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
What is the PFS hazard ratio and 95% CI for < 50 % Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) | ### Instruction: What is the PFS hazard ratio and 95% CI for < 50 % Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is < 50 % was 0.47 with a 95% confidence interval (CI) of (0.34, 0.65) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Tumor Burden is ≥50% patients | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for Tumor Burden is ≥50% patients
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with ≥50% Tumor Burden | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: What is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients with ≥50% Tumor Burden
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for ≥50% Tumor Burden patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: In the KarMMa-3 study, what is the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for ≥50% Tumor Burden patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for ≥50% Tumor Burden patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for ≥50% Tumor Burden patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at ≥50% Tumor Burden? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study for patients at ≥50% Tumor Burden?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for ≥50% Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel)? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: In the KarMMa-3 study, what’s the PFS hazard ratio and 95% CI for ≥50% Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for ≥50% Tumor Burden patients? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for ≥50% Tumor Burden patients?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for ≥50% Tumor Burden patients. Can you help? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for ≥50% Tumor Burden patients. Can you help?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the ≥50% Tumor Burden group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: What are the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) in KarMMa-3 study for patients in the ≥50% Tumor Burden group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the ≥50% Tumor Burden group? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: In the KarMMa-3 study, can you tell me the PFS hazard ratio and 95% CI of Idecabtagene Vicleucel (Ide-Cel) for patients in the ≥50% Tumor Burden group?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
What is the PFS hazard ratio and 95% CI for ≥50% Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study? | In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) | ### Instruction: What is the PFS hazard ratio and 95% CI for ≥50% Tumor Burden patients treated with Idecabtagene Vicleucel (Ide-Cel) in the KarMMa-3 study?
### Response: In the KarMMa-3 study, the progression-free survival (PFS) hazard ratio for Idecabtagene Vicleucel (Ide-Cel) in patients with Tumor Burden is ≥50% was 0.6 with a 95% confidence interval (CI) of (0.37, 0.97) |
Subsets and Splits